$VYGR
Voyager Therapeutics, Inc.

2023 Q1 Form 10-K Financial Statement

#000155837023002989 Filed on March 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $150.5M $40.91M $40.91M
YoY Change 22769.3% 45.72% 9.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.028M $30.98M $30.98M
YoY Change 17.87% 270.97% -16.82%
% of Gross Profit
Research & Development $18.57M $60.76M $60.76M
YoY Change 29.4% 333.41% -17.65%
% of Gross Profit
Depreciation & Amortization $1.075M $834.0K $6.200M
YoY Change -61.77% -43.72% 19.23%
% of Gross Profit
Operating Expenses $27.60M $91.74M $91.74M
YoY Change 25.39% 310.1% -17.37%
Operating Profit $122.9M -$50.84M
YoY Change -675.57% -30.94%
Interest Expense $1.864M $1.792M $1.792M
YoY Change 5912.9% -378.69% -559.49%
% of Operating Profit 1.52%
Other Income/Expense, Net $1.864M $2.653M $4.445M
YoY Change 5912.9% 308.15% 83.6%
Pretax Income $124.7M -$46.39M -$46.39M
YoY Change -685.15% -912.61% -34.84%
Income Tax $704.0K $16.00K $16.00K
% Of Pretax Income 0.56%
Net Earnings $124.0M -$46.41M -$46.41M
YoY Change -681.85% -912.89% -34.82%
Net Earnings / Revenue 82.43% -113.45% -113.45%
Basic Earnings Per Share $3.05 -$1.21
Diluted Earnings Per Share $2.94 -$1.21 -$1.21
COMMON SHARES
Basic Shares Outstanding 43.29M 38.61M 38.36M
Diluted Shares Outstanding 42.16M 38.36M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $273.3M $118.8M $118.8M
YoY Change 63.82% -10.33% -10.33%
Cash & Equivalents $268.3M $98.96M $98.96M
Short-Term Investments $4.993M $19.89M $19.89M
Other Short-Term Assets $3.983M $4.233M $5.012M
YoY Change 10.27% 148.85% 46.94%
Inventory
Prepaid Expenses
Receivables $25.33M $257.0K $257.0K
Other Receivables $0.00 $0.00 $382.0K
Total Short-Term Assets $302.6M $124.5M $124.5M
YoY Change 77.34% -8.92% -8.92%
LONG-TERM ASSETS
Property, Plant & Equipment $17.14M $17.86M $33.34M
YoY Change -11.54% -18.54% -39.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.515M $1.515M $1.515M
YoY Change -14.84% -14.84% -14.84%
Total Long-Term Assets $33.67M $34.86M $34.86M
YoY Change -37.1% -39.02% -39.02%
TOTAL ASSETS
Total Short-Term Assets $302.6M $124.5M $124.5M
Total Long-Term Assets $33.67M $34.86M $34.86M
Total Assets $336.3M $159.4M $159.4M
YoY Change 50.01% -17.8% -17.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.698M $2.566M $2.566M
YoY Change 208.17% 347.04% 347.04%
Accrued Expenses $7.639M $7.816M $10.65M
YoY Change -1.24% -28.62% -46.22%
Deferred Revenue $5.680M $59.38M
YoY Change -93.47% 75.23%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.94M $72.59M $72.59M
YoY Change -80.39% 42.39% 42.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.52M $21.30M $27.75M
YoY Change -46.17% -46.24% -41.98%
Total Long-Term Liabilities $20.52M $21.30M $27.75M
YoY Change -46.17% -46.24% -41.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.94M $72.59M $72.59M
Total Long-Term Liabilities $20.52M $21.30M $27.75M
Total Liabilities $119.3M $100.3M $100.3M
YoY Change -19.51% 1.55% 1.55%
SHAREHOLDERS EQUITY
Retained Earnings -$269.5M -$393.5M
YoY Change -26.85% 13.37%
Common Stock $43.00K $38.00K
YoY Change 13.16% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $217.0M $59.02M $59.02M
YoY Change
Total Liabilities & Shareholders Equity $336.3M $159.4M $159.4M
YoY Change 50.01% -17.8% -17.8%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $124.0M -$46.41M -$46.41M
YoY Change -681.85% -912.89% -34.82%
Depreciation, Depletion And Amortization $1.075M $834.0K $6.200M
YoY Change -61.77% -43.72% 19.23%
Cash From Operating Activities $123.6M -$12.24M -$12.51M
YoY Change 258.93% -209.37% -76.63%
INVESTING ACTIVITIES
Capital Expenditures $509.0K $933.0K $2.491M
YoY Change 1239.47% -368.88% 54.82%
Acquisitions
YoY Change
Other Investing Activities $15.00M $15.00M -$4.848M
YoY Change -175.15% -393.14% -107.18%
Cash From Investing Activities $14.49M $14.07M -$7.339M
YoY Change -172.46% -357.45% -111.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 31.31M 276.0K 1.110M
YoY Change 260783.33% 21.59% 81.37%
NET CHANGE
Cash From Operating Activities 123.6M -12.24M -12.51M
Cash From Investing Activities 14.49M 14.07M -7.339M
Cash From Financing Activities 31.31M 276.0K 1.110M
Net Change In Cash 169.4M 2.099M -18.74M
YoY Change 1072.87% -64.77% -244.22%
FREE CASH FLOW
Cash From Operating Activities $123.6M -$12.24M -$12.51M
Capital Expenditures $509.0K $933.0K $2.491M
Free Cash Flow $123.1M -$13.18M -$15.00M
YoY Change 257.85% -214.17% -72.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.99
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.98
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
152000
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2021Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38613891
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37918395
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001640266
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021 us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2022#OperatingExpenses
CY2022 us-gaap Operating Lease Income Comprehensive Income Extensible List
OperatingLeaseIncomeComprehensiveIncomeExtensibleList
http://fasb.org/us-gaap/2022#OperatingExpenses
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-37625
CY2022 dei Entity Registrant Name
EntityRegistrantName
Voyager Therapeutics, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3003182
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
64 Sidney Street
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2022 dei City Area Code
CityAreaCode
857
CY2022 dei Local Phone Number
LocalPhoneNumber
259-5340
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022 dei Trading Symbol
TradingSymbol
VYGR
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-69000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-275000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1992000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-60000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
382000
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
16000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5394000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3427000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3436000
CY2022Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
636000
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
1482000
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
113600000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43293369
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98959000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117433000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19889000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
15106000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
257000
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
732000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5394000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3427000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
124499000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
136698000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17857000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21920000
CY2022Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1515000
CY2021Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1779000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15485000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33458000
CY2022Q4 us-gaap Assets
Assets
159356000
CY2021Q4 us-gaap Assets
Assets
193855000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2566000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
574000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7816000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10950000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2832000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5571000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
59377000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
33886000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
72591000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
50981000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6450000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8210000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21295000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39609000
CY2022Q4 us-gaap Liabilities
Liabilities
100336000
CY2021Q4 us-gaap Liabilities
Liabilities
98800000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
726000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
727000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38613891
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37918395
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
452713000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
442259000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-219000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-393512000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347104000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
59020000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95055000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
159356000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
193855000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
40907000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37415000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
171128000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60764000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73787000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
108753000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30980000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37246000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34991000
CY2022 us-gaap Operating Expenses
OperatingExpenses
91744000
CY2021 us-gaap Operating Expenses
OperatingExpenses
111033000
CY2020 us-gaap Operating Expenses
OperatingExpenses
143744000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-50837000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-73618000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
27384000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1792000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-390000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1659000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2653000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2811000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7698000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4445000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2421000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9357000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46392000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-71197000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
36741000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-46408000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71197000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
36741000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-81000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-81000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-30000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46489000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71201000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
36711000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38356810
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37668947
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37132447
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38356810
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37668947
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37348514
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
99512000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2319000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1279000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
14499000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
36741000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
154320000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
918000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
10990000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71197000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95055000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
629000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
672000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
9153000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-81000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-46408000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
59020000
CY2022 us-gaap Profit Loss
ProfitLoss
-46408000
CY2021 us-gaap Profit Loss
ProfitLoss
-71197000
CY2020 us-gaap Profit Loss
ProfitLoss
36741000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
9344000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
11324000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
14934000
CY2022 us-gaap Depreciation
Depreciation
6191000
CY2021 us-gaap Depreciation
Depreciation
5165000
CY2020 us-gaap Depreciation
Depreciation
3817000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
16000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-349000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-27000
CY2022 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
2468000
CY2021 vygr Common Stock And Warrants To Purchase Equity Securities
CommonStockAndWarrantsToPurchaseEquitySecurities
-2460000
CY2020 vygr Common Stock And Warrants To Purchase Equity Securities
CommonStockAndWarrantsToPurchaseEquitySecurities
-7698000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-377000
CY2022 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-475000
CY2021 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-7280000
CY2020 vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
-10484000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1967000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1883000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
551000
CY2022 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-3462000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7816000
CY2021 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-2606000
CY2020 vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
7592000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3148000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3335000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6480000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3922000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3428000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
13439000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
23731000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1721000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-150676000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12509000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53525000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-96716000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2491000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1609000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12097000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
54848000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
15117000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
70403000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
50000000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
82632000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
195495000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7339000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
65906000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
112995000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
629000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2319000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
481000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
584000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
844000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1110000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
612000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3163000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18738000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12993000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19442000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119212000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106219000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86777000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100474000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119212000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106219000
CY2021 vygr Lease Exchange Cash Flow Amount
LeaseExchangeCashFlowAmount
664000
CY2020 vygr Lease Exchange Cash Flow Amount
LeaseExchangeCashFlowAmount
10818000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
14000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
80000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
831000
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Nature of business</b></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Voyager Therapeutics, Inc. (the “Company”) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines, with the goal of either halting or slowing disease progression or reduce symptom severity, therefore providing clinically meaningful impact to patients. The Company’s gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (“AAV”) based gene therapies that it believes have the potential to safely provide durable efficacy. The Company’s team of experts in the field of AAV gene therapy and neuroscience first identifies and selects diseases in which the Company believes an AAV gene therapy or other biological therapy will answer a high unmet medical need, be supported by target validation, offer an efficient path to human proof of biology, present robust preclinical pharmacology, and offer strong commercial potential. The Company then engineers and optimizes an AAV vector or other biological therapy for activity in, efficacy in, or delivery to, the targeted tissue or cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is identifying proprietary AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. The Company’s team has developed a proprietary AAV capsid discovery platform called TRACER<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (Tropism Redirection of AAV by Cell Type-Specific Expression of RNA) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (“BBB”). The TRACER discovery platform is a broadly applicable, functional RNA-based AAV capsid discovery platform that allows for rapid <i style="font-style:italic;">in vivo</i> evolution of AAV capsids with cell-specific transduction properties in multiple species, including non-human primates. The Company believes that the capsids it discovers through its TRACER discovery platform (“TRACER Capsids”) have the potential to significantly enhance the efficacy and safety of its single dose gene therapies, which it expects to be delivered with targeted surgical delivery or systemic infusions, as compared with conventional capsids.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has a history of incurring annual net operating losses. As of December 31, 2022, the Company had an accumulated deficit of $393.5 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities and funding from fees, milestone payments, and cost reimbursements associated with its prior collaborations with Sanofi Genzyme Corporation (“Sanofi Genzyme”) and AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company (collectively, “AbbVie”), and its ongoing collaborations with Neurocrine Biosciences, Inc. (“Neurocrine”), its option and license agreement with Pfizer, Inc. (“Pfizer”), and its option and license agreement with Novartis Pharma AG (“Novartis”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December 31, 2022, the Company had cash, cash equivalents, and marketable securities of $118.8 million. Based upon its current operating plan, the Company expects that its existing cash, cash equivalents, and marketable securities at December 31, 2022, together with the upfront payment received in February 2023 in connection with the Collaboration and License Agreement by and between the Company and Neurocrine dated as of January 8, 2023 (the “2023 Neurocrine Collaboration Agreement”), along with amounts expected to be received as reimbursement for development costs under the Company’s collaboration and license agreements with Neurocrine, will be sufficient to meet the Company’s planned operating expenses and capital expenditure requirements into 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</p>
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-393500000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
118800000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</p>
CY2022 us-gaap Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings
0
CY2022Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
111704000
CY2022Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
91000
CY2022Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
111613000
CY2021Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
115422000
CY2021Q4 vygr Money Market Funds And Marketable Securities Gross Unrealized Loss Before Tax
MoneyMarketFundsAndMarketableSecuritiesGrossUnrealizedLossBeforeTax
11000
CY2021Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
115411000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.15
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1500000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1800000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98959000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117433000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104440000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1515000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1779000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1779000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100474000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119212000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106219000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6199571
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7357134
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5956827
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6064344
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46408000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-71197000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
36741000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38356810
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37668947
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37132447
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38356810
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37668947
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37132447
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
216068
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38356810
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37668947
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37348514
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4233000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1701000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
696000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1360000
CY2022Q4 vygr Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
83000
CY2021Q4 vygr Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
350000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Significant Suppliers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has no financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign currency hedging arrangements. Financial instruments that potentially subject the Company to a concentration of credit risk are cash and cash equivalents. The Company’s cash is held in accounts at financial institutions that may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is dependent on third-party manufacturers to supply certain products for research and development activities in its programs. In particular, the Company relies on a sole manufacturer to supply it with specific vectors related to the Company’s research and development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p>
CY2022Q4 vygr Financial Instruments With Off Balance Sheet Risk Value
FinancialInstrumentsWithOffBalanceSheetRiskValue
0
CY2021Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3719000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
35064000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37833000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17207000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15913000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17857000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21920000
CY2022 us-gaap Depreciation
Depreciation
6200000
CY2021 us-gaap Depreciation
Depreciation
5200000
CY2020 us-gaap Depreciation
Depreciation
3800000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4559000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5022000
CY2022Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1895000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.12
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10950000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
4600000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
4600000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
6800000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
6800000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
6200000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
6200000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2022Q4 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.074
CY2022 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1380000
CY2021 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
838000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2832000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5571000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2832000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5571000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20294000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38608000
CY2022Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2021Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21295000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39609000
CY2021 us-gaap Restructuring Costs
RestructuringCosts
2600000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6095000
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
732000
CY2022 vygr Additions To Contract With Customer Assets
AdditionsToContractWithCustomerAssets
907000
CY2022 vygr Deductions To Contract With Customer Assets
DeductionsToContractWithCustomerAssets
1382000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
257000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
12096000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
269000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
11827000
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12778375
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11990940
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2405685
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9344000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11324000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14934000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9344000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11324000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14934000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5013193
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.69
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3681075
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.17
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
89012
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.07
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.066
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.023
CY2022 vygr Effective Income Tax Rate Reconciliation Deferred Rate Change Percent
EffectiveIncomeTaxRateReconciliationDeferredRateChangePercent
0.032
CY2021 vygr Effective Income Tax Rate Reconciliation Deferred Rate Change Percent
EffectiveIncomeTaxRateReconciliationDeferredRateChangePercent
0.049
CY2022 vygr Effective Income Tax Rate Reconciliation Nondeductible Expense General Business Credit Carryovers Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGeneralBusinessCreditCarryoversPercent
-0.035
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2744489
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.56
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2287000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
900000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
16000
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
16000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.052
CY2021 vygr Effective Income Tax Rate Reconciliation Nondeductible Expense General Business Credit Carryovers Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGeneralBusinessCreditCarryoversPercent
0.032
CY2020 vygr Effective Income Tax Rate Reconciliation Nondeductible Expense General Business Credit Carryovers Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseGeneralBusinessCreditCarryoversPercent
-0.206
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.046
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.038
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.050
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.019
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.213
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.319
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.050
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
47282000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
56756000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
32060000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
30122000
CY2022Q4 vygr Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
6318000
CY2021Q4 vygr Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
12012000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
17984000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11485000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4630000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7784000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1603000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1507000
CY2022Q4 vygr Deferred Tax Assets Capitalized
DeferredTaxAssetsCapitalized
14351000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
610000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
664000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-1000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
124837000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
120330000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
117416000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
107563000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
7421000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
12767000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
4231000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
9128000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
3190000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
3632000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
7000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
117400000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
107600000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9800000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
0
CY2022Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0

Files In Submission

Name View Source Status
0001558370-23-002989-index-headers.html Edgar Link pending
0001558370-23-002989-index.html Edgar Link pending
0001558370-23-002989.txt Edgar Link pending
0001558370-23-002989-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vygr-20221231.xsd Edgar Link pending
vygr-20221231x10k.htm Edgar Link pending
vygr-20221231x10k006.jpg Edgar Link pending
vygr-20221231xex10d36.htm Edgar Link pending
vygr-20221231xex10d43.htm Edgar Link pending
vygr-20221231xex10d44.htm Edgar Link pending
vygr-20221231xex10d45.htm Edgar Link pending
vygr-20221231xex10d46.htm Edgar Link pending
vygr-20221231xex21d1.htm Edgar Link pending
vygr-20221231xex23d1.htm Edgar Link pending
vygr-20221231xex31d1.htm Edgar Link pending
vygr-20221231xex31d2.htm Edgar Link pending
vygr-20221231xex32d1.htm Edgar Link pending
vygr-20221231_lab.xml Edgar Link unprocessable
vygr-20221231_pre.xml Edgar Link unprocessable
vygr-20221231x10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
vygr-20221231_def.xml Edgar Link unprocessable
vygr-20221231_cal.xml Edgar Link unprocessable